ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Altana is selling Altana Pharma to Nycomed for approximately $5.7 billion. Nycomed, a private Danish firm that primarily supplies drugs to hospitals in Europe, had sales last year of less than $1 billion; Altana Pharma has businesses in imaging, over-the-counter drugs, and prescription therapeutics and has annual sales of some $3 billion. "Combining Altana Pharma's market strength and research capabilities with Nycomed's strong position within development and in-licensing provides a sustainable future for the new company," says Altana CEO Nikolaus Schweickart. Hakan Bjorklund, CEO of Nycomed, adds that the deal will strengthen Nycomed's position in Europe while giving it a platform in fast growing markets such as Russia, Eastern Europe, and South America. Altana said earlier this year that it was exploring options for its drug unit in order to focus on Altana Chemie, its $1.2 billion-per-year specialty chemical business.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter